NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Geneos Therapeutics

Geneos Therapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://www.geneostx.com/

Last Round

Series A

Extension

Sep 27, 2023

Est. Valuation

$67M

Total Funding Raised

$54.5M

Company Overview

Geneos Therapeutics is a biotechnology company that develops DNA-based personalized immunotherapies for cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

personalized cancer vaccinePTCVneoantigenDNA immunotherapycancer vaccineelectroporationpersonalized medicineprecision oncologysolid tumor treatmentbiotherapeuticsneoantigen predictioncancer immunotherapyclinical stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Geneos Therapeutics Comparables

Compare Geneos Therapeutics with similar companies based on industry and business-model similarity.

Geneos Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nouscom
84%
Nexoplex Bio
78%
Evaxion A/S
78%

Geneos Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionSep 27, 2023
Series A ExtensionApr 12, 2023
Series A ExtensionMar 24, 2022
Series A ExtensionMar 3, 2021
Series AFeb 21, 2019

Key People

Founding team and executive leadership

Joann Peters

Chief Operating Officer

Executive Team

Geneos Therapeutics Investors

Notable investors and investment history

Geneos Therapeutics investors
InvestorRounds
Shanghai Healthcare CapitalSeries A Extension
3B FUTURE Health FundSeries A Extension
Flerie InvestSeries A Extension
Santé VenturesSeries A Extension, Series A
Santé VenturesSeries A Extension, Series A
Korea Investment PartnersSeries A Extension
Flerie ABSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 27, 2023

    $10M round led by Shanghai Healthcare Capital

  • Mar 24, 2022

    $17M round led by Flerie Invest.

Geneos Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Geneos Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Geneos Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range12
Year Founded2016
Last FundingSep 27, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.